Highlights
- Elixinol Wellness (ASX:EXL) reported AUD 3.6 million in Q3 2026 continuing-business sales.
- Q3 2026 continuing-business sales Revenue was AUD 3.6 million, up 6% year on year.
- Gross profit rose 27%, while gross Margin reached 42% in the quarter.
- Elixinol completed the divestment of its US Business in September 2026.
Elixinol Wellness (ASX:EXL) markets sustainable nutrition and wellness products through its Australian consumer brands and ingredients operations. Its recent disclosures address September-quarter sales, a completed US divestment and the proposed Vitable acquisition. Those developments place operational delivery, funding requirements and the next confirmed milestones in focus during the 2026 reporting period.
Quarterly Sales and Gross-Margin Development
Elixinol’s 14 October 2026 quarterly update reported AUD 3.6 million of sales revenue from the continuing Australian business, up 6% against the comparable period. Gross Profit increased 27%, while the quarterly gross margin reached 42%, seven percentage points above the prior comparison. The difference between revenue growth and gross-profit growth suggests an improved contribution from the product and channel mix, as reported by management. These figures exclude the divested US CBD operation and are described by the company as unaudited. They should not be combined with historical consolidated figures that included businesses no longer held.
Cost Control and Australian Brand Performance
The company reported operating expenses down 26% against the prior corresponding quarter. It also said revenue for the January-to-September 2026 period grew 6% and gross profit grew 34%. Within the business, The Healthy Chef generated reported revenue growth of 13% for the quarter, while Australian Primary Hemp ingredients revenue rose 81% from the comparative period. These are specific brand and channel measures, not a claim that every business unit expanded at the same rate. Elixinol reported positive underlying Operating Cash Flow for a fourth consecutive quarter, but its adjusted measure differs from the statutory Appendix 4C classification.
US Divestment and Proposed Vitable Acquisition
Elixinol completed the sale of its US operations in September 2026 as part of a narrower Australian operating focus. It also announced a binding agreement to acquire Vitable, an Australian personalised-supplement subscription platform, through an all-scrip transaction. The company said the proposed combination would exceed AUD 20 million of annual revenue on a pro forma 2026 basis. That figure is an illustrative combined measure, not historical revenue already earned by the enlarged group. Completion terms, any required approvals, share issuance and integration arrangements remain important distinctions when assessing the proposed expansion.
Cash, Integration and Reporting Risks
Elixinol disclosed AUD 0.9 million of cash at 30 September 2026. Although the update described improved underlying operating cash generation, a cash balance of this size requires careful monitoring alongside inventory, working-capital movements and Acquisition costs. The company is also moving from a broader geographic footprint towards a concentrated Australian portfolio while contemplating a new subscription business. Execution risks include integrating Vitable if the transaction completes, sustaining product margins, maintaining customer Demand and keeping expenditure controlled. Subsequent statutory cash-flow reporting and confirmed transaction completion will be important evidence.
Key Insights
Elixinol’s Q3 2026 results show a continuing Australian business with sales growth, higher gross margin and lower reported operating expenses. The divestment of US operations changes the comparison base, while the proposed Vitable purchase introduces a separate integration and share-issuance question. The AUD 0.9 million September cash balance means financial flexibility remains relevant despite improved underlying cash measures. Future reporting should clarify whether margins and working Capital remain consistent as the group’s business mix changes.




_11_19_2026_12_02_05_658284.jpg)

Please wait processing your request...